SNDX Q2 2021 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$22M-5892.9% margin

Net Income

-$23M-6044.9% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$263M

Total Liabilities

$48M

Stockholders' Equity

$215M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$22M	-$17M	-34.5%
Net Income	-$23M	-$17M	-34.3%